Michael Rome
Director/Board Member bij Remix Therapeutics, Inc.
Vermogen: - $ op 31-03-2024
Profiel
Michael Rome is currently the Director at Remix Therapeutics, Inc. and the Vice President at Foresite Life Sciences Corp.
He previously worked as the Director at Pharvaris NV from 2019 to 2020, Independent Director at Theseus Pharmaceuticals, Inc. from 2021 to 2024, Director & Vice President at FS Development Corp.
from 2020 to 2021, and Independent Director at Kinnate Biopharma, Inc. from 2019 to 2024.
Dr. Rome has an undergraduate degree from the University of California, Los Angeles and a doctorate degree from the California Institute of Technology.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
KINNATE BIOPHARMA, INC.
-.--% | 03-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Michael Rome
| Bedrijven | Functie | Begin |
|---|---|---|
Foresite Life Sciences Corp.
 Foresite Life Sciences Corp. Financial ConglomeratesFinance Foresite Life Sciences Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in January 2021 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-01-2021 |
Remix Therapeutics, Inc.
 Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Director/Board Member | - |
Eerdere bekende functies van Michael Rome
| Bedrijven | Functie | Einde |
|---|---|---|
| KINNATE BIOPHARMA INC. | Director/Board Member | 03-04-2024 |
| THESEUS PHARMACEUTICALS, INC. | Director/Board Member | 14-02-2024 |
| FS DEVELOPMENT CORP. | Director/Board Member | 01-02-2021 |
| PHARVARIS N.V. | Director/Board Member | 31-12-2020 |
| PARDES BIOSCIENCES, INC. | Director/Board Member | - |
Opleiding van Michael Rome
| University of California, Los Angeles | Undergraduate Degree |
| California Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PHARVARIS N.V. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. BiotechnologyHealth Technology Theseus Pharmaceuticals, Inc. engages in the development of pan-variant kinase inhibitors. It focuses on the discovery, development and commercialization of transformative targeted therapies. The company was founded by William C. Shakespeare, David C. Dalgarno, Iain D. Dukes, Wei Sheng Huang and Victor M. Rivera on December 29, 2017 and is headquartered in Cambridge, MA. | Health Technology |
Kinnate Biopharma, Inc.
 Kinnate Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA. | Health Technology |
FS Development Corp.
 FS Development Corp. Financial ConglomeratesFinance FS Development Corp. operates as a blank check company. It is for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Jim Tananbaum in June 2020 and is headquartered in San Francisco, CA. | Finance |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA. | Health Technology |
FS Development Corp. II
 FS Development Corp. II Financial ConglomeratesFinance FS Development Corp. II is a blank check company, which formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more entities. The company was founded by James B. Tananbaum on August 21, 2020 and is headquartered in Larkspur, CA. | Finance |
Foresite Life Sciences Corp.
Foresite Life Sciences Corp. Financial ConglomeratesFinance Foresite Life Sciences Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded in January 2021 and is headquartered in San Francisco, CA. | Finance |
